IQVIA Wins Snowflake’s “Marketplace Healthcare and Life Sciences Partner of the Year” Award
RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions…
RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions…
Second Quarter 2022 Financial Highlights Generated revenues of $24.8 million during second quarter 2022, an…
BOSTON–(BUSINESS WIRE)–PSG, a leading growth equity firm partnering with software and technology-enabled services companies to…
Second Quarter 2022 Highlights Revenue increased 17.0% to $42.0 million Total orders were flat at…
Companies are building immersive technologies and guiding the future of entertainment, gaming, virtual experiences, and…
– Received FDA acceptance of BLA for omidubicel with Priority Review; PDUFA target action date…
Plenity Q2 product revenue increased 312% year-over-year to $9.0 million Gross profit in Q2 increased…
– Q2 2022 revenue increases 67% vs. Q1 2022 – – WiSA DS gaining design…
– Company Allocated Over $356 Million in Green Bond Net Proceeds to Eligible Green Projects…
CHICAGO–(BUSINESS WIRE)–OppFi Inc. (NYSE:OPFI) (“OppFi” or the “Company”), a leading financial technology platform that powers…
Initiated Phase 1 pharmacokinetic trial for ETX-155 with expected results in Q4 2022 Capital now…
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar…
REYKJAVIK, Iceland, Aug. 15, 2022 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company…
Choice Renovations Canada signs a multi-billion dollar real estate investment group as its newest client,…
HONG KONG, Aug 15, 2022 – (ACN Newswire) – On August 2, 2022, R&G Pharmastudies…
HONG KONG, Aug 15, 2022 – (ACN Newswire) – Driven by the brand promise of…
Technology Industry Veterans J. Michael Dodson and David Roberson Join Company’s Board SAN JOSE, Calif.–(BUSINESS…
Committed to being carbon net zero by 2040 and has developed an innovative Network Construction…
Phase III CANOPY-A trial did not meet primary endpoint of disease-free survival in patients with…
Addex to Receive CHF850,000 ($900,000) of Additional Funding; Addex’s Reserved Indications Expanded to include Chronic…